M
Michael Desmond Creagh
Researcher at Royal Cornwall Hospital
Publications - 6
Citations - 398
Michael Desmond Creagh is an academic researcher from Royal Cornwall Hospital. The author has contributed to research in topics: Octapharma & Randomized controlled trial. The author has an hindex of 5, co-authored 6 publications receiving 301 citations.
Papers
More filters
Journal ArticleDOI
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
K. John Pasi,Savita Rangarajan,Pencho Georgiev,Tim Mant,Michael Desmond Creagh,Toshko Lissitchkov,David H. Bevan,Steve Austin,Charles R. M. Hay,Inga Hegemann,Rashid S. Kazmi,Pratima Chowdary,Liana Gercheva-Kyuchukova,Vasily Mamonov,Margarita Timofeeva,Chang-Heok Soh,Pushkal Garg,Akshay Vaishnaw,Akin Akinc,Benny Sørensen,Margaret V. Ragni +20 more
TL;DR: Once‐monthly subcutaneous administration of fitusiran resulted in dose‐dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.
Journal ArticleDOI
Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline.
John Hanley,A McKernan,Michael Desmond Creagh,S. Classey,Paul McLaughlin,Nicholas J. Goddard,P J Briggs,S Frostick,Paul L. F. Giangrande,Jonathan T. Wilde,Jecko Thachil,Pratima Chowdary +11 more
TL;DR: Haemophilia Centre, Royal Victoria Infirmary, Newcastle upon Tyne; †Department of Haematology, Derby Hospitals NHS Foundation Trust, Derby; ‡Haemophile Centre,Royal Cornwall Hosp hospitals NHS Trust, Truro; and ‡ Haemophili Centre, Guys and St. Thomas’ NHS Foundation trust, London.
Journal ArticleDOI
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors
Margaret V. Ragni,Pencho Georgiev,Tim Mant,Michael Desmond Creagh,Toshko Lissitchkov,David H. Bevan,Steve Austin,Charles R. M. Hay,Inga Hegemann,Rashid S. Kazmi,Pratima Chowdary,Savita Rangarajan,Chang-Heok Soh,Akin Akinc,Angela M. Partisano,Benny Sorenson,K. John Pasi +16 more
TL;DR: The updated safety, pharmacodynamic (PD) effect, and clinical activity of fitusiran in patients with hemophilia with inhibitors as well as long term data from the Phase 1/2 extension study are reported.
Journal ArticleDOI
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B
K. John Pasi,Pencho Georgiev,Tim Mant,Michael Desmond Creagh,Toshko Lissitchkov,David H. Bevan,Steve Austin,Charles R. M. Hay,Brigit Brand,Rashid S. Kazmi,Pratima Chowdary,Margaret V. Ragni,Jihong Chen,Akin Akinc,Benny Sørensen,Savita Rangarajan +15 more
TL;DR: Emerging clinical data suggest that targeting AT could be a promising approach for restoring hemostatic balance in hemophilia, and the potential for low volume subcutaneous administration, monthly dosing, and applicability to patients with Hemophilia A and B with and without inhibitors make ALN-AT3 a potentially encouraging investigational therapy.
Journal ArticleDOI
Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation
Pratima Chowdary,Augustine Tang,Dale Watson,Martin Besser,Peter William Collins,Michael Desmond Creagh,Hafiz Qureshi,Margaret Rokicka,Tim Nokes,Paul Diprose,Ravi Gill +10 more
TL;DR: PCCs offer a potential alternative to FFP in the management of perioperative bleeding unrelated to oral anticoagulant therapy, and the rate of thromboembolic events was below rates in the literature for similar procedures.